SCHEMBL6894498

SCHEMBL6894498

CC(O)SC(O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AHCY P23526 9/20 0.59
PRMT5 O14744 1/20 0.59
WDR77 Q9BQA1 1/20 0.59
ADORA3 P0DMS8 3/20 0.58
NADK O95544 1/20 0.58
ADORA2B P29275 2/20 0.58
TSHR P16473 1/20 0.58
LMNA P02545 1/20 0.58
THRB P10828 1/20 0.58
BLM P54132 1/20 0.58
KMT2A Q03164 1/20 0.58
HSP90AA1 P07900 1/20 0.58
HSP90B1 P14625 1/20 0.58
ADORA2A P29274 1/20 0.58
ADORA1 P30542 1/20 0.58
DOT1L Q8TEK3 1/20 0.58
DPP4 P27487 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL101380 0.89 AHCY (0.62) AHCYPRMT5WDR77ADORA3NADK
SCHEMBL800346 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B
SCHEMBL16300875 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B
SCHEMBL800381 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B
SCHEMBL13173634 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B
SCHEMBL18520788 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B
SCHEMBL22326787 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B
SCHEMBL21413837 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B
SCHEMBL22326785 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B
SCHEMBL13134675 0.88 PRMT5 (0.64) AHCYPRMT5WDR77ADORA3ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482977-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2004-12-08 EP disclosed
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells AGOURON PHARMACEUTICALS INC. 2004-03-04 US disclosed
WO-2003074083-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells APRT, MTAP, TYMP AHCY 62/4885PRMT5 585/4885WDR77 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.